RecruitingNot ApplicableNCT06538610

The 5-FU Holter Study

Feasibility Study of Ambulatory Holter Monitoring While Receiving Infusional Fluorouracil (5-FU) Chemotherapy

Sponsor

University of Auckland, New Zealand

Enrollment

10 participants

Start Date

Nov 1, 2024

Study Type

INTERVENTIONAL

Conditions

Gastrointestinal Malignancy

Summary

To assess the feasibility of using ambulatory ECG monitoring (Holter monitor) for patients receiving 5-FU chemotherapy

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Holter monitor for people with gastrointestinal malignancy. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEHolter monitor

Holter monitor fitted from start of 5-FU infusion (Day 1) to 5-FU infusion ending (Day 3). Holter monitor to be worn for approximately 46-48 hours.

Locations(1)

Auckland City Hospital

Auckland, New Zealand

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06538610

Related Trials

The Erector Spinae Plane Block For Gastrointestinal Malignancy Pain Treatment (EGIPT)

NCT072113864 locations